Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | ST6GAL1 | P15907 | 6/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoramidic Acid SCHEMBL109383 | 0.95 | NT5E (0.56) | NT5ELMNATHRBMTORMDM2 | |
| Phosphoramidic Acid SCHEMBL112639 | 0.91 | NT5E (0.60) | NT5ELMNATHRBMTORMDM2 | |
| Phosphoramidic Acid SCHEMBL109330 | 0.84 | POLB (0.48) | NT5ELMNATHRBMTORMDM2 | |
| Phosphoramidic Acid SCHEMBL110972 | 0.82 | P2RY2 (0.49) | P2RY2 | |
| Phosphoramidic Acid SCHEMBL110386 | 0.79 | POLB (0.47) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL31279764 | 0.78 | NT5E (0.69) | NT5ELMNATHRBMTORMDM2 | |
| Phosphoramidic Acid SCHEMBL110862 | 0.78 | P2RY2 (0.48) | P2RY2 | |
| SCHEMBL6571375 | 0.78 | NT5E (0.68) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL27938161 | 0.78 | NT5E (0.68) | NT5ELMNATHRBMTORMDM2 | |
| Phosphoric Acid SCHEMBL16859831 | 0.77 | NT5E (0.67) | NT5ELMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-05-03 | — | — | US | disclosed |
| EP-2424874-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125200-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | PNP, TYMP, MTAP | NT5E 253/4885LMNA 2992/4885THRB 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.